Visual evoked potential changes following Botox administration in patients with blepharospasm
- PMID: 36652021
- DOI: 10.1007/s10792-023-02639-9
Visual evoked potential changes following Botox administration in patients with blepharospasm
Abstract
Purpose: To examine visual evoked potential (VEP) changes following botulinum toxin type A (BTA) administration in patients with blepharospasm.
Methods: Patients diagnosed with blepharospasm receiving BTA administration were included in the study. Three groups, a control group and two study groups (patients examined 14 days after BTA administration-Study Group 1, and patients examined 28 days after BTA administration-Study Group 2) were evaluated. Dilated fundus examinations were performed following detailed ophthalmological examinations and VEP tests. Keypoint (Dantec, Denmark) and ISCEV criteria were adopted for pattern VEP (PVEP) recording. BTA was applied in the form of local injections at a total 15-30 units, at 2.5-5 units per injection.
Results: A mean 19.4 ± 3.2 units of BTA was used for each eye. N70 (ms), P100 (ms), and P100 (uV) values were statistically significantly lower in both study groups following drug administrations compared to the control group (p < 0.001 for all). Significant positive correlation was observed between increased P100 amplitudes and age in the control group (p = 0.008, r = 0.200). Significant negative correlation was observed between the BTA units used and decreased P100 amplitudes in both study groups 1 and 2 following drug administrations (p = 0.017, r = - 0.180 and p = 0.043, r = - 0.153, respectively).
Conclusion: VEP may be an important method in the diagnosis and follow-up of blepharospasm and in determining the success of drug administration and additional therapeutic requirements.
Keywords: Blepharospasm; Botulinum toxin; P100; Visual evoked potential.
© 2023. The Author(s), under exclusive licence to Springer Nature B.V.
Similar articles
-
Treatment Effects of Botulinum Toxin Injection and Acupuncture on Blepharospasm Assessed by the Change in Lower Eyelid Tension.Curr Eye Res. 2019 Jun;44(6):679-683. doi: 10.1080/02713683.2019.1578379. Epub 2019 Feb 22. Curr Eye Res. 2019. PMID: 30724635
-
Long-term efficacy and safety of botulinum toxin A injections to treat blepharospasm and hemifacial spasm.Clin Exp Ophthalmol. 2014 Apr;42(3):254-61. doi: 10.1111/ceo.12165. Epub 2013 Aug 4. Clin Exp Ophthalmol. 2014. PMID: 23844601
-
[Cost-utility analysis of two formulations of botulinum toxin type A in the treatment of blepharospasm and cervical dystonia in Spain].Rev Neurol. 2018 Dec 16;67(12):465-472. Rev Neurol. 2018. PMID: 30536360 Spanish.
-
[Essential blepharospasm and hemifacial spasm: characteristic of the patient, botulinum toxin A treatment and literature review].Arq Bras Oftalmol. 2006 Jan-Feb;69(1):23-6. doi: 10.1590/s0004-27492006000100005. Epub 2006 Feb 10. Arq Bras Oftalmol. 2006. PMID: 16491229 Review. Portuguese.
-
Botulinum toxin in blepharospasm and oromandibular dystonia: comparing different botulinum toxin preparations.Eur J Neurol. 2006 Feb;13 Suppl 1:21-9. doi: 10.1111/j.1468-1331.2006.01441.x. Eur J Neurol. 2006. PMID: 16417594 Review.
References
-
- Barbosa ER, Silva HC, Haddad MS et al (1996) Blepharospasm: treatment with botulinum toxin. Rev Hosp Clin Fac Med Sao Paulo 51:220–223 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical